Assessing current AI trends in drug development: Operational efficiency and overcoming challenges (part 2)

Published on February 13, 2025

Artificial intelligence (AI) has shifted from experimental projects to a valuable pharmaceutical research and development (R&D) asset. While the pace of adoption varies across the industry, AI is enabling organizations to address inefficiencies, reduce timelines, and improve decision-making at critical drug development stages. Building on the insights from part 1, which highlighted how companies are […]

Continue reading on website
Other news

Steps to Process Development Optimization

February 10, 2025
Featured Contributor: Daniel Giroux, VP of Biologics DevelopmentThe development and production of biologics can be a complex process. And the manufacture of biopharmaceuticals requires that processes be developed and validated so that product specifications can be met to create a safe and effective biologic drug. Steps can be taken at each stage of the development and manufacturing of biologics to

Gene-edited iPSC: the role of Automation in Cell Line Development

February 14, 2025
Precise gene editing is crucial for the development of cell-based therapies, particularly allogeneic approaches, where enhancing cell function, improving persistence, and reducing immunogenicity are key objectives. Developers often face the challenge of combining multiple gene knockouts with knock-ins, resulting in an average of six to eight gene edits. However, traditional manual genome editing p